AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for ATP-sensitive inward rectifier potassium channel 11

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for ion channels.

 Fig. 1. The sreening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14654

UPID:

KCJ11_HUMAN

Alternative names:

IKATP; Inward rectifier K(+) channel Kir6.2; Potassium channel, inwardly rectifying subfamily J member 11

Alternative UPACC:

Q14654; B4DWI4; E9PNK0; Q2M1H7; Q58EX3; Q8IW96

Background:

ATP-sensitive inward rectifier potassium channel 11 (KCNJ11), also known as Kir6.2, plays a pivotal role in cellular physiology by regulating potassium flow. This receptor, controlled by G proteins, allows potassium to flow into cells, a process essential for maintaining the cell's electrical stability. KCNJ11 partners with ABCC9 to form ATP-sensitive potassium channels (KATP), crucial in cardiac and smooth muscle functions.

Therapeutic significance:

KCNJ11's malfunction is linked to several metabolic disorders, including Hyperinsulinemic hypoglycemia, familial, 2 (HHF2), and various forms of diabetes mellitus. These conditions underscore the protein's critical role in glucose homeostasis and insulin regulation. Understanding KCNJ11's function and its genetic variants offers a pathway to targeted treatments for these metabolic diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.